You are here:
LinkedIn-button

About us

Company
profile

Even the most promising vaccines don’t always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies.

The Netherlands-based Intravacc part of the Utrecht Science Park location Bilthoven. is one of the world’s leading organizations with many years of experience in translational vaccinology. As an established independent clinical development and manufacturing organization (CDMO) in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials in humans.

LEARN MORE
ANNUAL REPORT
LinkedIn-button

Our Vision

Reduction of human diseases through innovative vaccine technology

LinkedIn-button

Our Mission

To partner with (non) governmental
agencies and private entities to help
to reduce the disease burden

LinkedIn-button

Intravacc to the point

  • Founded in 2013
  • HQ at Utrecht Science Park Bilthoven
  • Experts in vaccinology
  • Clinical development & manufacturing organization
  • 2000+ m2 state-of the art facilities, incl BSL-2/3 & GMP
  • ISO 9001 certified
  • >140 high qualified employees
  • 50+ customers worldwide
  • 300+ scientific publications in peer reviewed journals
LinkedIn-button

About us

Latest News

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine Bilthoven, the Netherlands, 13 April 2021 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive preclinical data for its OMV based Lyme disease vaccine. Publication of this study in the peer reviewed scientific journal Vaccine titled “Vaccination…

  • Neisserial OMV based Lyme vaccine elicit high antibody titers in mice
  • Further evidence for Intravacc's versatile multi-disease OMV platform
  • Data are published in peer reviewed journal Vaccine
Read more

Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine

Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine Bilthoven, the Netherlands, 7 April 2021 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive pre-clinical results for its SARS-CoV-2 Outer Membrane Vesicle (OMV) based recombinant Spike protein (rSp) candidate nose spray…

  • Intranasal administration of OMV-Spike protected against challenge with SARS-CoV-2
  • Intranasal vaccine administration has significant advantages over injectables
  • OMV technology is a powerful vaccine platform for future pandemics
Read more

Intravacc Announces Appointment of Nathalie Laarakker as Chief Financial Officer

Intravacc Announces Appointment of Nathalie Laarakker as Chief Financial Officer Bilthoven, the Netherlands, 24 March 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced the appointment of Nathalie Laarakker as Chief Financial Officer and member of the company’s executive management team, with effect from April 1, 2021. Mrs. Nathalie Laarakker…

Read more
LinkedIn-button

About us

Media

LinkedIn-button

About us

Join our Community

Are you interested in becoming part of an innovative community, to learn alongside top scientists, to work with state-of-the art equipment, to get an inside look of and contribute to the biotech sector, where industry leaders, government, universities and international non-governmental organizations collaborate? Then Intravacc is the place for you.

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.